Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

464.02
Delayed Data
As of Aug 17
 -4.52 / -0.96%
Today’s Change
325.35
Today|||52-Week Range
543.55
+26.40%
Year-to-Date
Seattle Genetics' Adcetris Granted Priority Review by FDA
Aug 17 / Zacks.com - Paid Partner Content
Regeneron vs. Alexion: Which Stock is a Better Pick Post Q2 Earnings?
Aug 14 / Zacks.com - Paid Partner Content
Novo Nordisk's Semaglutide Shows Remarkable Results in Study
Aug 17 / Zacks.com - Paid Partner Content
Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward
Aug 14 / TheStreet.com - Paid Partner Content
Orbimed Advisors Llc Buys Cigna Corp, Clovis Oncology Inc, Gilead Sciences Inc, Sells...
Aug 17 / GuruFocus News - Paid Partner Content
Bb Biotech Ag Buys AveXis Inc, Sells Regeneron Pharmaceuticals Inc, Puma Biotechnolog...
Aug 11 / GuruFocus News - Paid Partner Content
Vanguard Sells Medtronic, Cigna in 2nd Quarter
Aug 17 / GuruFocus News - Paid Partner Content
Forget Teva (TEVA), Buy These 4 Drug Stocks Instead
Aug 11 / Zacks.com - Paid Partner Content
Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst
Aug 17 / TheStreet.com - Paid Partner Content
Puma (PBYI) Q2 Loss Narrower than Expected, Nerlynx in Focus
Aug 10 / Zacks.com - Paid Partner Content
Regeneron's (REGN) RSV Drug Suptavumab Fails NURSERY Trial
Aug 16 / Zacks.com - Paid Partner Content
Geron (GERN) Q2 Loss Narrows, Sales Miss Estimates, Stock Up
Aug 10 / Zacks.com - Paid Partner Content
Spectrum (SPPI) Initiates Phase II Study for Cancer Drug
Aug 16 / Zacks.com - Paid Partner Content
Inovio (INO) Q2 Loss Narrower Than Expected, Revenues Beat
Aug 09 / Zacks.com - Paid Partner Content
Ophthotech's Fovista Combo Regimen Disappoints in Phase III
Aug 16 / Zacks.com - Paid Partner Content
Biotech Stock Roundup: Q2 Earnings from Regeneron, Kite & More, FibroGen Up on IPF Da...
Aug 09 / Zacks.com - Paid Partner Content
Biotech Stock Roundup: Regeneron Drops RSV Antibody, Gilead HIV Drug Gets Priority Re...
Aug 16 / Zacks.com - Paid Partner Content
The Zacks Analyst Blog Highlights: ExxonMobil, MasterCard, Shell, Regeneron and BP
Aug 08 / Zacks.com - Paid Partner Content